BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
90 hedge funds and large institutions have $38.5M invested in BRAINSTORM CELL THERAPUTC in 2020 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 27 increasing their positions, 20 reducing their positions, and 18 closing their positions.
56% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 18
35% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 20
13% more funds holding
Funds holding: 80 → 90 (+10)
0.32% more ownership
Funds ownership: 1.44% → 1.76% (+0.32%)
13% less call options, than puts
Call options by funds: $4.5M | Put options by funds: $5.17M
67% less capital invested
Capital invested by funds: $115M → $38.5M (-$76.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$3.47M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.37M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
+$2.47M |
| 4 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$1.58M |
| 5 |
Morgan Stanley
New York
|
+$956K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$6.24M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$1.08M |
| 3 |
WG
Winton Group
London,
United Kingdom
|
-$776K |
| 4 |
SG Americas Securities
New York
|
-$771K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$728K |
BCLI Hedge Fund Activity: Q4 2020 in Review
90 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q4 2020, worth a combined $38.5M — down 67% from $115M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new BCLI positions and 18 closed out — a net gain of 10 holders — while 27 added to existing stakes and 20 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $3.47M. The largest seller was Invesco, exiting entirely with an estimated $6.24M sold.
- 90 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q4 2020, up from 80 in Q3 2020.
- Funds reported $38.5M of BRAINSTORM CELL THERAPUTC stock for Q4 2020, down 67% quarter-over-quarter.
- 28 funds opened new BRAINSTORM CELL THERAPUTC positions in Q4 2020 and 18 closed out, a net change of +10 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q4 2020 was JP Morgan Chase, an estimated $3.47M added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q4 2020 was Invesco, an estimated $6.24M sold.
Based on aggregated 13F filings for Q4 2020.